Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives Consensus Rating of “Buy” from Analysts

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has earned a consensus rating of “Buy” from the eleven analysts that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, seven have given a buy rating and three have issued a strong buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $33.6667.

A number of equities research analysts have weighed in on TEVA shares. Bank of America boosted their target price on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Scotiabank started coverage on Teva Pharmaceutical Industries in a report on Friday, December 5th. They set a “sector outperform” rating and a $35.00 target price on the stock. Jefferies Financial Group raised their price objective on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. JPMorgan Chase & Co. raised their price target on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a report on Tuesday, December 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, October 8th.

Insiders Place Their Bets

In other news, insider Mark Sabag sold 216,892 shares of the firm’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $28.73, for a total transaction of $6,231,307.16. Following the completion of the sale, the insider owned 52,828 shares of the company’s stock, valued at $1,517,748.44. This trade represents a 80.41% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Richard Daniell sold 115,468 shares of the firm’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $28.68, for a total transaction of $3,311,622.24. Following the completion of the sale, the vice president owned 48,384 shares of the company’s stock, valued at $1,387,653.12. The trade was a 70.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 622,060 shares of company stock valued at $17,076,965 over the last 90 days. 0.49% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several hedge funds and other institutional investors have recently modified their holdings of the company. Grove Bank & Trust lifted its holdings in shares of Teva Pharmaceutical Industries by 300.0% in the 4th quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock worth $31,000 after purchasing an additional 750 shares in the last quarter. Cromwell Holdings LLC raised its holdings in Teva Pharmaceutical Industries by 40.3% during the third quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock worth $44,000 after buying an additional 629 shares during the last quarter. Advisors Asset Management Inc. bought a new position in shares of Teva Pharmaceutical Industries in the second quarter valued at $41,000. Rothschild Investment LLC grew its holdings in shares of Teva Pharmaceutical Industries by 97.0% during the third quarter. Rothschild Investment LLC now owns 2,738 shares of the company’s stock valued at $55,000 after buying an additional 1,348 shares during the last quarter. Finally, JFS Wealth Advisors LLC grew its holdings in shares of Teva Pharmaceutical Industries by 257.1% during the third quarter. JFS Wealth Advisors LLC now owns 2,778 shares of the company’s stock valued at $56,000 after buying an additional 2,000 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA opened at $31.66 on Friday. The business has a 50-day simple moving average of $29.51 and a two-hundred day simple moving average of $22.48. Teva Pharmaceutical Industries has a 12-month low of $12.47 and a 12-month high of $33.42. The stock has a market cap of $36.31 billion, a PE ratio of 52.77, a PEG ratio of 1.80 and a beta of 0.66. The company has a quick ratio of 0.82, a current ratio of 1.11 and a debt-to-equity ratio of 2.31.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.